Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:0874)
Hong Kong
· Delayed Price · Currency is HKD 17.48
-0.02 (-0.11%)
Apr 3, 2025, 4:08 PM HKT
HKG:0874 Revenue
In the year 2024, Guangzhou Baiyunshan Pharmaceutical Holdings Company had annual revenue of 74.99B CNY, down -0.69%. Guangzhou Baiyunshan Pharmaceutical Holdings Company had revenue of 15.93B in the quarter ending December 31, 2024, a decrease of -8.07%.
Revenue
74.99B CNY
Revenue Growth
-0.69%
P/S Ratio
0.36
Revenue / Employee
2.67M CNY
Employees
28,048
Market Cap
44.21B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 74.99B | -522.58M | -0.69% |
| Dec 31, 2023 | 75.52B | 4.73B | 6.68% |
| Dec 31, 2022 | 70.79B | 1.77B | 2.57% |
| Dec 31, 2021 | 69.01B | 7.34B | 11.90% |
| Dec 31, 2020 | 61.67B | -3.28B | -5.05% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Jan 1, 2018 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 31.39B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |